1. Home
  2. OCCI vs TTRX Comparison

OCCI vs TTRX Comparison

Compare OCCI & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Credit Company Inc.

OCCI

OFS Credit Company Inc.

HOLD

Current Price

$3.08

Market Cap

97.4M

Sector

Finance

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$5.53

Market Cap

107.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OCCI
TTRX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
2
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.4M
107.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OCCI
TTRX
Price
$3.08
$5.53
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
218.0K
60.9K
Earning Date
12-11-2023
05-31-2026
Dividend Yield
24.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.19
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.62
$2.57
52 Week High
$6.43
$6.75

Technical Indicators

Market Signals
Indicator
OCCI
TTRX
Relative Strength Index (RSI) 38.15 59.64
Support Level $2.80 $3.92
Resistance Level $3.08 $6.75
Average True Range (ATR) 0.09 0.60
MACD -0.04 -0.06
Stochastic Oscillator 5.33 45.55

Price Performance

Historical Comparison
OCCI
TTRX

About OCCI OFS Credit Company Inc.

OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: